Why it matters nowDual point-of-care tests could serve as a cost-effective, patient-friendly, and provider-friendly alternative to conventional testing in clinical and field settings, particularly in resource-limited environments where validated screening tools may help reduce HIV and syphilis incidence.
Why it matters nowEstablishing quantitative immunological benchmarks may assist regulatory agencies in evaluating vaccine performance during approval pathways.
Why it matters nowMultiplex serological approaches offer potential solutions for classifying individuals infected more than six months prior and for measuring seroprevalence in very low-transmission settings, addressing key challenges in SARS-CoV-2 serological surveillance.
Why it matters nowThe findings challenge the assumption of complete lifelong protection from homologous dengue re-infection and provide context for understanding limited vaccine efficacy against DENV-2 in recent trials. The incomplete protection may have implications for dengue transmission dynamics.
